Aug 2026· Journal of Gastrointestinal Cancer· Vol 57· 0 citations· 26 references
Medicine
TL;DR
Treatment selection in the post- BREAKWATER era should integrate molecular context, patient fitness, and remaining evidence gaps, as well as the management of frail or oxaliplatin-ineligible patients, maintenance therapy, local treatment integration, and sequencing after frontline encorafenib exposure.
This structured narrative review separately examines mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) and microsatellite-stable/mismatch repair-proficient (MSS/pMMR) disease and distinguish established treatments from investigational strategies and identify the remaining evidence gaps.
Alireza Tojjari, Shamim Pourbahrighesmat, Shahd Alkhazna et al.· Critical reviews in oncology...· 0 citations
BACKGROUND
The BRAF V600E mutation in metastatic colorectal cancer (mCRC) is associated with a poor prognosis when treated with conventional chemotherapy regimens. Recent advances in research have shown promise in using combined BRAF inhibitor and an EGFR inhibitor to treat BRAF V600E-mutated mCRC, with international g...
Simar Gill, Ned Liu, Elaine Ngan et al.· Clinical colorectal cancer· 0 citations
Background Metastatic colorectal cancer (mCRC) is associated with poor prognosis and low survival rates, with acquired resistance limiting the durability of standard therapies. Mesenchymal-epithelial transition factor (MET) amplification is a rare but potentially actionable molecular alteration that has been implicated...
Ying Huang, Pei Shu, Shi-Yuan Gu et al.· Frontiers in Oncology· 0 citations
Comprehensive genomic profiling (CGP) has been increasingly implemented in clinical practice; however, only a limited proportion of patients ultimately receive genomically matched therapies. The
BRAF
V600E mutation is extremely rare in gastric cancer, and effective targeted treatment strategies remain undefined....
BRAFV600‐mutant metastatic colorectal cancer comprises a biologically distinct and clinically aggressive subset of metastatic colorectal cancer. Early attempts to apply single‐agent BRAFV600 inhibition failed because of rapid acquired resistance and reactivation of mitogen‐activated protein kinase signaling. Over the l...
I. Dirven, C. Ang, C. Bertels et al.· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
